Trials / Not Yet Recruiting
Not Yet RecruitingNCT07074418
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 - EMPA [10-20]
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin 10 MG then Placebo | Taking Empagliflozin first |
| DRUG | Placebo then Empagliflozin 10 MG | Taking the Empagliflozin in second |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-07-20
- Last updated
- 2026-01-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07074418. Inclusion in this directory is not an endorsement.